Study shows Jardiance reduces cardiovascular risks in patients with Type 2 diabetes
According to the announcement, people with this type of diabetes who also have risk factors for cardiovascular disease have an average life expectancy that is decreased by approximately 12 years and that approximately 50 percent of diabetes patients die as a result of cardiovascular disease.
With Jardiance, a 38 percent reduction was reported in deaths attributed to a fatal heart attack or stroke.
“These results are both novel and exciting for the millions of people living with Type 2 diabetes at risk for cardiovascular disease," Bernard Zinman, lead investigator and director of the Diabetes Center at Mount Sinai Hospital, said. "Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality. In this study, empagliflozin was shown to prevent one out of three cardiovascular deaths.”
This study was carried out with the addition of standard care for cardiovascular disease patients and diabetes patients. Jardiance's primary use is to lower the amount of blood sugar.
Diabetes affects approximately 29 million Americans and 387 million people across the globe.
Organizations in this story
Boehringer-Ingelheim 900 Ridgebury Rd Ridgefield, CT - 06877